Description
Wedica (Trelagliptin) indicate as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This is a highly selective dipeptidyl peptidase-4 inhibitor that is typically use as an add on treatment when the first line treatment of metformin is not achieving the expected glycemic goals; though it has been approved for use as a first line treatment when metformin cannot use.
Therapeutic Class
Pharmacology
It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulin tropic polypeptide, incretin hormones that play an important role in blood glucose regulation. The inhibition of DPP-4 increases insulin secretion depending on blood glucose concentration, thereby controlling blood glucose levels. It is indicated for the treatment of type 2 diabetes.
Dosage & Administration
100 mg of Trelagliptin administer to adults once weekly by mouth. This has lesser hypoglycemic events and 4 and 12-fold more potent than Alogliptin and Sitagliptin.
Contraindications
Study subjects meeting any of the following criteria not include in this study:
- Under treatment with trelagliptin for type 2 diabetes at the start of screening.
- Diagnosis of type 1 diabetes.
- Severe renal impairment or renal failure (e.g., eGFR < 30 mL/min/1.73 m2 or on dialysis).
- Serious heart disease or a cerebrovascular disorder, or a serious pancreatic, blood, or other disease.
- History of gastrointestinal resection.
- A proliferative diabetic retinopathy.
- Malignancy.
- A history of hypersensitivity or allergy to DPP-4 inhibitors.
- Who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.
- Who need to add or discontinue concomitant medication or change the dose during the study period.
- Require treatment with a prohibited concomitant medication during the study period.
- Assessed as ineligible for any other reason by the investigators.
Side Effects
Among 901 domestic clinical trial cases up to the time of approval, 103 cases ( 11.4%) showed clinical results that included abnormalities and side effects. These mainly included hypoglycemia, nasopharyngitis, and elevated lipase.
Given the appearance of serious side effects such as hypoglycemia (0.1~5%) , administer medication in conjunction with close observation of patient status. Other DPP-4 inhibitors report to present serious hypoglycemia in combination with Sulfonylurea medications as well as some cases of loss of consciousness. Moreover, decreased blood sugar from the use of this medication, once confirmed, can remedied by giving sucrose. However, hypoglycemia resulting from a combination with glucosidase inhibitors treat with fructose.
Pregnancy & Lactation
Precautions & Warnings
(provide cautious dosage to the following patients): The following patients or circumstances
- Patients with moderate kidney function disorder
- Patients undergoing treatment with sulfonylurea drugs or insulin medication [there are reports of severe hypotension with use in combination with other DPP-4 inhibitors]
- Hypopituitarism or hypoadrenalism
- Malnutrition, starvation, irregular eating patterns, insufficient eating, or hyposthenia
- Vigorous exercise
- Patients who consume excessive alcohol
Storage Conditions
Store at 25°C; excursions permitted to 15°-30°C. Dispense medication in the original container to protect from exposure to high humidity and light. Keep out of the reach of children.
Visit our another product here:
Reviews
There are no reviews yet.